BRISTOL-MYERS SQUIBB COMPANY |
Market Closed -
Other stock markets
|
After market 06:09:22 pm | |||
| 44.7 USD | -8.51% |
|
44.95 | +0.56% |
| Apr. 25 | Health Care Drops Amid Mixed Earnings -- Health Care Roundup | DJ |
| Apr. 25 | Sector Update: Health Care Stocks Decline Late Afternoon | MT |
Financials (USD)
| Sales 2024 * | 45.85B | Sales 2025 * | 46.33B | Capitalization | 99.03B |
|---|---|---|---|---|---|
| Net income 2024 * | -5.37B | Net income 2025 * | 10.42B | EV / Sales 2024 * | 3.03 x |
| Net Debt 2024 * | 39.92B | Net Debt 2025 * | 31.58B | EV / Sales 2025 * | 2.82 x |
| P/E ratio 2024 * |
-18.4
x | P/E ratio 2025 * |
8.83
x | Employees | 34,100 |
| Yield 2024 * |
4.95% | Yield 2025 * |
5.17% | Free-Float | 69.13% |
More Fundamentals
* Assessed data
More news
Latest transcript on Bristol-Myers Squibb Company
More recommendations
More press releases
More news
| 1 day | -8.51% | ||
| 1 week | -7.45% | ||
| Current month | -17.57% | ||
| 1 month | -14.45% | ||
| 3 months | -9.90% | ||
| 6 months | -21.04% | ||
| Current year | -12.88% |
1 week
44.37
49.56
1 month
44.3754.48
Current year
44.3755.04
1 year
44.3769.10
3 years
44.3781.44
5 years
42.4881.44
10 years
42.4881.44
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 53 | 15-01-31 | |
David Elkins
DFI | Director of Finance/CFO | 55 | 19-11-19 |
Greg Meyers
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Phyllis Yale
BRD | Director/Board Member | 66 | 19-11-19 |
Peter Arduini
BRD | Director/Board Member | 59 | 16-03-31 |
Derica Rice
BRD | Director/Board Member | 59 | 20-08-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 12.97% | 215 M€ | +12.27% | - | |
| 4.99% | 2 M€ | -.--% | ||
| 4.01% | 18 M€ | +3.04% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-25 | 44.7 | -8.51% | 44,973,389 |
| 24-04-24 | 48.86 | -0.27% | 16,057,141 |
| 24-04-23 | 48.99 | -0.31% | 9,153,290 |
| 24-04-22 | 49.14 | +0.43% | 7,929,534 |
| 24-04-19 | 48.93 | +1.30% | 10,303,913 |
Delayed Quote Nyse, April 25, 2024 at 04:00 pm EDT
More quotes
Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques.
The United States account for 70.1% of net sales.
Sector
Pharmaceuticals
Calendar
2024-05-07
- Annual General Meeting
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
HOLD
Number of Analysts
27
Last Close Price
48.86
USD
Average target price
55.8
USD
Spread / Average Target
+14.21%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -12.88% | 99.03B | |
| +24.17% | 562B | |
| -6.33% | 358B | |
| +19.90% | 322B | |
| +7.95% | 297B | |
| +13.45% | 219B | |
| +6.04% | 199B | |
| -10.51% | 196B | |
| -12.26% | 149B | |
| -6.47% | 146B |
- Stock Market
- Equities
- BMY Stock
